PHAR (Pharming Group N.V.) Forward P/E Multiple
Pharming Group N.V. relies on a steady cash flow from orphan drug sales to fund new research. The company's forward P/E, which informs this chart via GURU.Markets data, currently stands at 34.60. The business maintains monopoly control over protein production within a narrow niche, while a team of leading biologists is driven by the opportunity to save patients' lives.
Analytical breakdowns for Pharming Group N.V.
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
- company profitability and valuation multiples indicators:
PHAR - Final Profit|Projected Future Earnings Pharming Group N.V.|PHAR - P/E Multiple|Future Price to Earnings Pharming|PHAR - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming Group NV|PHAR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Pharming Group|PHAR - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months pharming.com|PHAR - Earnings per share growth this year|Earnings growth forecast for next year Pharming Group N.V.
- total revenue and sales volume data:
Summary company analytics:Pharming Group
Investors use this indicator to identify fundamental valuation supports for an asset. The metric is calculated as the ratio of the current share price to the projected earnings for the upcoming period. The forward P/E history of Pharming Group N.V. (PHAR) visualizes the dynamics of market expectations and the impact of the cost of capital on the business valuation. A compression of the multiple reflects the risks of losing market share. For Pharming Group N.V. (PHAR), this is critical due to pressure from genetic engineering behemoths in the orphan disease niche.
Competitors of Pharming Group N.V. (PHAR)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings ADPT|Forward P/E Multiple Celldex Corp|Future Price to Earnings Aurinia Pharmaceuticals (AUPH)|biocryst.com - Price to Future Earnings Ratio|Forward P/E Multiple VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Projected Price to Earnings Ratio|PHVS - Future Price to Earnings|Price to Expected Earnings Ratio ABCL|TRML: Forward P/E Multiple|precigen.com - Future Price to Earnings Multiple|NKTR (Nektar Therapeutics Inc.) - Forward P/E Multiple|Forward P/E Multiple Upstream Bio, Inc.|Future Price to Earnings Zenas Biopharma, Inc. (ZBIO)|IMNM (Immunome Bio) - Future Price to Earnings Multiple|Future Price to Earnings Gossamer Bio, Inc. GOSS|KALV - Projected Price to Earnings|Septerna - Forward P/E Multiple|Market Cap to Projected Earnings Pieris Pharma PVLA|Savara Corp (SVRA) - Future Price to Earnings|Price to Future Earnings Ratio RIGL|ANAB (AnaptysBio, Inc.) - Forward P/E Multiple|ATXS - Forward Price to Earnings Multiple|Projected Price to Earnings ENGN (enGene)|RAPT (RAPT Therapeutics Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple JBIO (Aerovate Therapeutics)|Forward Price to Earnings Multiple Aclaris Therapeutics, Inc|KYTX - Future Price to Earnings|Future Price to Earnings Multiple TLSA (tizianalifesciences.com)|Cabaletta Bio (CABA) - Future Price to Earnings|Projected Price to Earnings Ratio Ventyx Biosciences Inc. (VTYX)|Projected Price to Earnings THTX|Forward P/E Multiple Avalo Therapeutics Inc|Future Price to Earnings Eledon Pharmaceuticals (ELDN)|AGEN: Price to Expected Earnings Ratio|Climb Bio - Projected Price to Earnings|Future Price to Earnings Multiple ZURA|ATYR - Future Price to Earnings|ADAG (Adagene) - Price to Future Earnings Ratio|IMA (ikenaoncology.com) - Projected Price to Earnings|STTK - Market Cap to Projected Earnings|Projected Price to Earnings EQ|Future Price to Earnings CNTB|Projected Price to Earnings IMUX (Immunic, Inc.)|Market Cap to Projected Earnings atarabio.com|Future Price to Earnings InflaRx IFRX|XFOR (x4pharma.com) - Price to Expected Earnings Ratio|Adicet - Forward P/E Multiple|Future Price to Earnings Multiple CELU (Celularity Inc.)|INMB: Forward P/E Multiple|Barinthus Biotherapeutics Corp (BRNS) - Forward P/E Multiple|Future Price to Earnings Kezar Life Sciences|SABS: Future Price to Earnings Multiple|Future Price to Earnings Akari Therapeutics Plc (AKTX)|ENLV: Price to Expected Earnings Ratio|Forward P/E Multiple QTTB (Q32 Bio)|Future Price to Earnings Multiple GOVX|Edesa Biotech, Inc. - Forward P/E Multiple|IBIO - Forward P/E Multiple|carismatx.com (CARM) - Future Price to Earnings|XTL Biopharmaceuticals Ltd - Future Price to Earnings Multiple|Future Price to Earnings Bolt Biotherapeutics Inc.|Projected Price to Earnings HCW Biologics Inc (HCWB)|Forward P/E Multiple APVO|Forward P/E Multiple AIM ImmunoTech, Inc. (AIM)|Aditxt, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple GRI|XORTX - Forward P/E Multiple|Market Cap to Projected Earnings Vyome Therapeutics HIND|Revelation Biosciences (REVB) - Future Price to Earnings|Projected Price to Earnings indaptusrx.com|Future Price to Earnings Scinai Immunotherapeutics Ltd.|Projected Price to Earnings CalciMedica Corp (CALI)|Projected Price to Earnings AFMD (Affimed)|Forward P/E Multiple allakos.com (ALLK)|Future Price to Earnings HOOKIPA Pharma HOOK|IGMS: Price to Future Earnings Ratio|iTeos Therapeutics, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Ocean Biomedical Inc|TC BioPharm (Holdings) PLC (TCBP) - Future Price to Earnings|Price to Expected Earnings Ratio THRD (Third Harmonic Bio Inc)
